Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2011 (2011), Article ID 519526, 5 pages
http://dx.doi.org/10.4061/2011/519526
Review Article

Prescribing Medications in Patients with Decompensated Liver Cirrhosis

Department of Gastroenterology, Bombay Hospital and Medical Research Centre, New Prabhadevi Road, Prabhadevi, Mumbai 400 025, India

Received 21 February 2011; Accepted 24 May 2011

Academic Editor: Richard Guan

Copyright © 2011 Deepak N. Amarapurkar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Rodighiero, “Effects of liver disease on pharmacokinetics. An update,” Clinical Pharmacokinetics, vol. 37, no. 5, pp. 399–431, 1999. View at Google Scholar · View at Scopus
  2. F. Delcò, L. Tchambaz, R. Schlienger, J. Drewe, and S. Krähenbühl, “Dose adjustment in patients with liver disease,” Drug Safety, vol. 28, no. 6, pp. 529–545, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Verma and N. Kaplowitz, “Diagnosis, management and prevention of drug-induced liver injury,” Gut, vol. 58, no. 11, pp. 1555–1564, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. R. Senior, “Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?” Clinical Pharmacology and Therapeutics, vol. 85, no. 3, pp. 331–334, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. G. Abboud and N. Kaplowitz, “Drug-induced liver injury,” Drug Safety, vol. 30, no. 4, pp. 277–294, 2007. View at Google Scholar · View at Scopus
  6. http://www.fda.gov/cder/livertox/prevention/m0093/rfld002.htm.
  7. Physicians' Desk Reference, Medical Economics Inc., Montvale, NJ, USA, 56th edition, 2002.
  8. C. Lammert, E. Bjornsson, A. Niklasson, and N. Chalasani, “Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events,” Hepatology, vol. 51, no. 2, pp. 615–620, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. Larrey, “Epidemiology and individual susceptibility to adverse drug reactions affecting the liver,” Seminars in Liver Disease, vol. 22, no. 2, pp. 145–155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. R. A. Nathwani and N. Kaplowitz, “Drug Hepatotoxicity,” Clinics in Liver Disease, vol. 10, no. 2, pp. 207–217, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. G. C. Farrell, Drug Induced Liver Disease, Churchill Livingstone, London, UK, 1994.
  12. G. Marino, H. J. Zimmerman, and J. H. Lewis, “Management of drug-induced liver disease,” Current Gastroenterology Reports, vol. 3, no. 1, pp. 38–48, 2001. View at Google Scholar · View at Scopus
  13. J. H. Lewis, “Drug-induced liver disease,” Medical Clinics of North America, vol. 84, no. 5, pp. 1275–1311, 2000. View at Google Scholar · View at Scopus
  14. J. H. Lewis, “The rational use of potentially hepatotoxic medications in patients with underlying liver disease,” Expert Opin Drug Saf, vol. 1, no. 2, pp. 159–172, 2002. View at Google Scholar · View at Scopus
  15. H. J. Zimmerman, Hepatotoxicity. The Adverse Effects of Drugs and Other Chemical on the Liver, Lippincot Williams & Wilkins, Philadelpha, Pa, USA, 2nd edition, 1999.
  16. N. Rolando, J. Philpott-Howard, and R. Williams, “Bacterial and fungal infection in acute liver failure,” Seminars in Liver Disease, vol. 16, no. 4, pp. 389–402, 1996. View at Google Scholar · View at Scopus
  17. J. Reichen, “Prescribing in liver disease,” Journal of Hepatology, vol. 26, no. 1, pp. 36–40, 1997. View at Google Scholar · View at Scopus
  18. B. E. Senousy, S. I. Belal, and P. V. Draganov, “Hepatotoxic effects of therapies for tuberculosis,” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 10, pp. 543–556, 2010. View at Publisher · View at Google Scholar · View at PubMed
  19. S. Agal, R. Baijal, S. Pramanik et al., “Monitoring and management of antituberculosis drug induced hepatotoxicity,” Journal of Gastroenterology and Hepatology, vol. 20, no. 11, pp. 1745–1752, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. I. Tegeder, J. Lötsch, and G. Geisslinger, “Pharmacokinetics of opiods in liver disease,” Clinical Pharmacokinetics, vol. 37, no. 1, pp. 17–40, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Bamji and L. B. Cohen, “Endoscopic sedation of patients with chronic liver disease,” Clinics in Liver Disease, vol. 14, no. 2, pp. 185–194, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. N. Chandok and K. D. S. Watt, “Pain management in the cirrhotic patient: the clinical challenge,” Mayo Clinic Proceedings, vol. 85, no. 5, pp. 451–458, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. O. Picker, C. Beck, and B. Pannen, “Liver protection in the perioperative setting,” Best Practice and Research: Clinical Anaesthesiology, vol. 22, no. 1, pp. 209–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Rossi, D. N. Assis, M. Awsare et al., “Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations,” Drug Safety, vol. 31, no. 3, pp. 261–270, 2008. View at Google Scholar · View at Scopus
  25. S. K. Khalid, J. Lane, V. Navarro, and G. Garcia-Tsao, “Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis,” Clinical Gastroenterology and Hepatology, vol. 7, no. 9, pp. 994–999, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. I. Sokol, A. Cheng, W. H. Frishman, and C. S. Kaza, “Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure,” Journal of Clinical Pharmacology, vol. 40, no. 1, pp. 11–30, 2000. View at Google Scholar · View at Scopus
  27. R. Vuppalanchi and N. Chalasani, “Statins for hyperlipidemia in patients with chronic liver disease: are they safe?” Clinical Gastroenterology and Hepatology, vol. 4, no. 7, pp. 838–839, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus